Immune‐related adverse events in hepatitis treated with thiopurine‐based immunosuppressants: A case report
Open Access
- 19 March 2023
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 14 (13), 1208-1211
- https://doi.org/10.1111/1759-7714.14859
Abstract
An 82-year-old man was treated with ipilimumab and nivolumab for malignant pleural mesothelioma. Although he was previously treated with prednisolone (1 mg/kg/day) for immune-related adverse event (irAE) hepatitis by a previous doctor, he still had worsening liver function and was transferred to our hospital. Blood tests and imaging findings were negative for autoimmune and infectious hepatitis, and liver biopsy results were consistent with irAE hepatitis. Steroid pulse therapy improved liver function, but tapering to prednisolone (1 mg/kg/day) again worsened his liver function. Concomitant use of mycophenolate mofetil was initiated, but no improvement in liver function was observed, therefore azathioprine, a thiopurine immunosuppressant, was administered in combination with steroids. During the course of treatment, hepatic dysfunction due to azathioprine was suspected, and the concomitant use of mercaptopurine and prednisolone was started. Afterward, the liver function improved, and the prednisolone dose was gradually reduced to 10 mg/day. This is a rare case in which a thiopurine-based immunosuppressant was effective against irAE hepatitis, therefore thiopurine-based immunosuppressants may be effective against steroid-refractory hepatitis.Keywords
This publication has 7 references indexed in Scilit:
- First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743Annals of Oncology, 2022
- Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse EventsJournal of Thoracic Oncology, 2021
- Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to DurvalumabInternal Medicine, 2020
- Pembrolizumab-Induced Delayed-Onset HepatitisCase Reports in Gastroenterology, 2020
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitisThe Esophagus, 2003
- Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1.2001